ID   NZM036
AC   CVCL_S428
SY   NZM36
DR   BioSample; SAMN14558335
DR   Cosmic; 2007669
DR   Wikidata; Q54931568
RX   PubMed=23658559;
RX   PubMed=32567790;
CC   HLA typing: A*02:01,11:01; B*44:02,48:01; C*05:01,08:01 (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
ST   Source(s): PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 13,16
ST   D19S433: 13
ST   D21S11: 28,31.2
ST   D2S1338: 22,23
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   D8S1179: 10,13
ST   FGA: 23,24
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-04-25; Version: 11
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//